Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative ... system (dysautonomia manifested by problems with blood pressure, bowel and bladder symptoms, erectile dysfunction, ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

No specific neuroprotective treatment is available so far, leaving a survival time of usually less than 10 years after the ...

To learn more, the researchers enrolled 428 people, aged between 40-99, with a clinical diagnosis of Parkinson’s, dementia with Lewy bodies, multiple system atrophy and pure autonomic failure.

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy (MSA). The topline data showed that ATH434 produced clinically and statistically significant ...

While Parkinson's disease accounts for 80% of all Parkinsonism cases, other conditions — multiple system atrophy or corticobasal degeneration — can also cause the symptoms. "The Eagles will be ...

To learn more, the researchers enrolled 428 people, aged between 40 and 99, with a clinical diagnosis of Parkinson’s, dementia with Lewy bodies, multiple system atrophy or pure autonomic failure.

Intravenous immunoglobulin (IVIG) has anti-inflammatory properties with multiple mechanisms of action. IVIG inhibits autoreactive T cells, suppresses autoantibodies through anti-idiotypic ...

Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of ...

Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the ...